{"id":"ozoralizumab","rwe":[{"pmid":"41763966","year":"2026","title":"Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial).","finding":"","journal":"Annals of the rheumatic diseases","studyType":"Clinical Study"},{"pmid":"41753109","year":"2026","title":"Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41717779","year":"2026","title":"Impact of Anti-Drug Antibodies and Neutralising Antibodies on Safety and Efficacy of Ozoralizumab in Rheumatoid Arthritis.","finding":"","journal":"Modern rheumatology","studyType":"Clinical Study"},{"pmid":"41523451","year":"2025","title":"Ozoralizumab-Induced Multifocal Demyelinating Neuropathy in a Patient With Rheumatoid Arthritis.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41381211","year":"2025","title":"Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials.","finding":"","journal":"RMD open","studyType":"Clinical Study"}],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Tumor necrosis factor","category":"target"},{"label":"TNF","category":"gene"},{"label":"Active","category":"status"},{"label":"Rheumatoid arthritis","category":"indication"},{"label":"Taisho Pharmaceutical Co., Ltd.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Taisho Pharmaceutical Co., Ltd.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OZORALIZUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:20:16.341336+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:20:22.074334+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OZORALIZUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:20:22.377153+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: TNF-alpha inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:23.473151+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743054/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:23.127160+00:00"}},"allNames":"nanozora","offLabel":[],"synonyms":["ozoralizumab","ozoralizumab (genetical recombination)","nanozora","ATN-103","PF-5230896"],"timeline":[{"date":"2022-09-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Taisho Pharmaceutical Co., Ltd.)"}],"approvals":[{"date":"2022-09-26","orphan":false,"company":"TAISHO PHARMACEUTICAL CO., LTD.","regulator":"PMDA"}],"brandName":"Nanozora","ecosystem":[{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"target":"Tumor necrosis factor","targets":[{"gene":"TNF","source":"DrugCentral","target":"Tumor necrosis factor","protein":"Tumor necrosis factor"}],"modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Nanozora is a monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-α), preventing its interaction with cell surface receptors and subsequent activation of downstream signaling pathways that promote inflammation and immune cell activation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5723","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OZORALIZUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OZORALIZUMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:14:36.330515","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:24.740790+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"adalimumab","drugSlug":"adalimumab","fdaApproval":"2002-12-31","relationship":"same-target"},{"drugName":"certolizumab pegol","drugSlug":"certolizumab-pegol","fdaApproval":"2008-04-22","relationship":"same-target"},{"drugName":"etanercept","drugSlug":"etanercept","fdaApproval":"1998-11-02","relationship":"same-target"},{"drugName":"golimumab","drugSlug":"golimumab","fdaApproval":"2009-04-24","relationship":"same-target"},{"drugName":"infliximab","drugSlug":"infliximab","fdaApproval":"1998-08-24","relationship":"same-target"},{"drugName":"lenalidomide","drugSlug":"lenalidomide","fdaApproval":"2005-12-27","patentExpiry":"Mar 8, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"mesalazine","drugSlug":"mesalazine","fdaApproval":"1987-12-24","relationship":"same-target"},{"drugName":"plecanatide","drugSlug":"plecanatide","fdaApproval":"2017-01-19","patentExpiry":"Sep 15, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"thalidomide","drugSlug":"thalidomide","fdaApproval":"1998-07-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"ozoralizumab","indications":{"approved":[{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"adalimumab","brandName":"adalimumab","genericName":"adalimumab","approvalYear":"2002","relationship":"same-target"},{"drugId":"certolizumab-pegol","brandName":"certolizumab pegol","genericName":"certolizumab pegol","approvalYear":"2008","relationship":"same-target"},{"drugId":"etanercept","brandName":"etanercept","genericName":"etanercept","approvalYear":"1998","relationship":"same-target"},{"drugId":"golimumab","brandName":"golimumab","genericName":"golimumab","approvalYear":"2009","relationship":"same-target"},{"drugId":"infliximab","brandName":"infliximab","genericName":"infliximab","approvalYear":"1998","relationship":"same-target"},{"drugId":"lenalidomide","brandName":"lenalidomide","genericName":"lenalidomide","approvalYear":"2005","relationship":"same-target"},{"drugId":"mesalazine","brandName":"mesalazine","genericName":"mesalazine","approvalYear":"1987","relationship":"same-target"},{"drugId":"plecanatide","brandName":"plecanatide","genericName":"plecanatide","approvalYear":"2017","relationship":"same-target"},{"drugId":"thalidomide","brandName":"thalidomide","genericName":"thalidomide","approvalYear":"1998","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04077567","phase":"PHASE3","title":"An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2019-10-01","conditions":["Rheumatoid Arthritis"],"enrollment":401,"completionDate":"2023-04-28"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"05ZCK72TXZ","INN_ID":"9369","UMLSCUI":"C4519741","chemblId":"CHEMBL1743054","ChEMBL_ID":"CHEMBL1743054","KEGG_DRUG":"D09944","DRUGBANK_ID":"DB12014","IUPHAR_LIGAND_ID":"9638"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Taisho Pharmaceutical Co., Ltd.","relationship":"Current Owner"}],"publicationCount":40,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 27","pmid":"41763966","title":"Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial).","journal":"Annals of the rheumatic diseases"},{"date":"2026 Feb 11","pmid":"41753109","title":"Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series.","journal":"Journal of clinical medicine"},{"date":"2026 Feb 20","pmid":"41717779","title":"Impact of Anti-Drug Antibodies and Neutralising Antibodies on Safety and Efficacy of Ozoralizumab in Rheumatoid Arthritis.","journal":"Modern rheumatology"},{"date":"2025 Dec","pmid":"41523451","title":"Ozoralizumab-Induced Multifocal Demyelinating Neuropathy in a Patient With Rheumatoid Arthritis.","journal":"Cureus"},{"date":"2025 Dec 11","pmid":"41381211","title":"Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials.","journal":"RMD open"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Taisho Pharmaceutical Co., Ltd.","companyId":"taisho-pharmaceutical-co-ltd","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2022-09-26T00:00:00.000Z","mah":"TAISHO PHARMACEUTICAL CO., LTD.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:24.740790+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}